Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes plc completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA‑approved narcolepsy drug LUMRYZ and a commercial team experienced in sleep medicine. The deal was executed via an Irish court‑sanctioned scheme of arrangement.
Avadel shareholders became entitled to receive $21.00 in cash per share plus one contingent value right that may pay an additional $1.50 per share if a specified milestone in the CVR agreement is met. Avadel will be delisted from Nasdaq and deregistered under U.S. securities laws.
To finance the Acquisition, Alkermes borrowed $1.525 billion under new senior secured term loan A and B facilities maturing in 2031 and used approximately $750 million of its cash. A prior bridge term loan facility of about $1.5 billion was terminated. Alkermes states the transaction is expected to be accretive in 2026 and to enhance its revenue growth profile while expanding its neuroscience portfolio and late‑stage pipeline in sleep and other neurological disorders.
Alkermes plc Director and CEO Richard F. Pops reported two transactions in ordinary shares. On February 5, 2026, he acquired 149,580 ordinary shares at no cost from the vesting of performance-based restricted stock units granted in February 2023 after a three-year performance period.
On the same date, he disposed of 62,230 ordinary shares at $33.55 per share. Following these transactions, Pops beneficially owned 1,377,740 ordinary shares directly.
Alkermes plc senior executive Christian Todd Nichols reported equity transactions in company ordinary shares. On February 5, 2026, he acquired 21,127 ordinary shares at no cost upon vesting of performance-based restricted stock units granted in 2023 after a three-year performance period.
On the same date, he reported a disposition of 6,389 ordinary shares at $33.55 per share. Following these transactions, Nichols directly owned 100,946 ordinary shares of Alkermes plc.
Alkermes plc executive Blair Curtis Jackson reported new share awards and a related share disposition. On February 5, 2026, Jackson acquired 28,810 ordinary shares at no cost from the vesting of performance-based restricted stock units granted on February 23, 2023, covering a three-year period that ended December 31, 2025. The vesting followed the determination that certain performance goals were achieved and a relative total shareholder return adjustment was applied.
On the same date, Jackson disposed of 8,626 ordinary shares at $33.55 per share in a transaction coded "F," and held 221,552 ordinary shares directly after these transactions.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported equity compensation activity in the company’s ordinary shares. On February 5, 2026, he acquired 25,352 ordinary shares at no cost upon vesting of performance-vesting restricted stock units granted on February 23, 2023.
The vesting followed achievement of pre-set performance goals and application of a relative total shareholder return modifier, and represents the final vesting event under the 2023 PRSU awards. On the same date, 7,454 shares were disposed of at $33.55 per share (code F), typically indicating shares withheld or sold to cover tax obligations, leaving 75,638 shares held directly.
Alkermes plc executive David Joseph Gaffin reported equity compensation activity. On February 5, 2026, he acquired 25,352 ordinary shares at no cost when performance-vesting RSUs granted on February 23, 2023 vested after a three-year performance period ending December 31, 2025.
The same day, he disposed of 7,619 ordinary shares at $33.55 per share in a transaction coded “F.” After these transactions, he directly beneficially owned 223,107 ordinary shares of Alkermes plc.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported option exercises and share sales in Alkermes ordinary shares. On February 2, 2026, he exercised an employee stock option for 5,000 shares at an exercise price of $19.34, converting it into ordinary shares. The filing shows two same-day sales of ordinary shares: 5,000 shares sold at a weighted average price of $34.2449 and 4,000 shares sold at $33.54. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the reported trades, Hopkinson directly owns 57,740 ordinary shares and holds 26,356 employee stock options that are fully vested in accordance with their terms.
Alkermes plc director Shane Cooke reported exercising employee stock options and selling the resulting shares. On 02/02/2026, he exercised 61,200 employee stock options at an exercise price of
That same day, he sold 29,087 ordinary shares at a weighted average price of
The filing notes that the exercise and sale of expiring options were executed under a Rule 10b5-1 trading plan adopted on
A holder of Alkermes plc ordinary shares has filed a Rule 144 notice to sell 61,200 shares. The shares are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026 and an aggregate market value of $2,115,674.45.
The 61,200 ordinary shares were acquired on 02/02/2026 through the exercise of employee stock options in a broker-assisted cashless exercise. The filing notes that 165,117,509 ordinary shares were outstanding, providing context for the size of the planned sale.
Alkermes plc insider Craig Hopkinson has filed a notice to sell ordinary shares under Rule 144. The filing covers 9,000 ordinary shares to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $305,384.28 and 165,117,509 shares outstanding.
The shares come from a broker-assisted cashless exercise of 5,000 employee stock options on 02/02/2026 and vesting of restricted stock unit awards totaling 4,000 shares during February 2025. The form also lists several prior ordinary share sales by Hopkinson over the past three months with disclosed gross proceeds.
FAQ
What is the current stock price of Alkermes Plc (ALKS)?
What is the market cap of Alkermes Plc (ALKS)?
